statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.

 Latest Ratings for ANAB...

Wall Street analysts on Friday are seeing some exciting opportunities in the tech and biotechnology sectors, and doled out some positive notes. Let’s find out if retail investors are nodding to these cues.Morgan Stanley Upgrades Arm (ARM) to Overweight:&nbsp;Analysts at Morgan Stanley are bullish on Arm Holdings PLC,citing the company's potential for growth in the emerging edge artificial intelligence (AI) space. They upgraded the stock from Equal Weight to Overweight and raised the price target to $190, up from $107.&nbsp;Retail investors on Stocktwits also seem to agree, with bullish sentiment (66/100) following the upgrade. One popular <a href="https://stocktwits.com/Rocket_5227/message/580033550">post</a> even pointed out that the stock is "filling the first gap up at around $175" after the price target increase.<figure class="image"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARM_Stocktwits_sentiment_Jul_19_484bd7e946.png" alt="ARM Stocktwits sentiment Jul 19.png" width="1324" height="314"><figcaption>ARM Stocktwits sentiment Jul 19</figcaption></figure>UBS Upgrades Accenture (ACN) to Buy:&nbsp;UBS upgraded Accenture Plc to Buy from Neutral, citing the company's opportunity for multiple expansion as the market anticipates accelerating revenue growth in AI.&nbsp;However, Stocktwits sentiment is more neutral (53/100) on ACN, possibly due to some hesitation over the company's recent acquisition spree — like Logic (a retail technology services firm) and True North Solutions (an industrial engineering solutions provider) — and recent underwhelming financial performance.The company missed earnings estimates in its last quarter and its stock is down 4.60% year-to-date (YTD). It will be interesting to see if Accenture can meet analyst expectations and turn around investor sentiment.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ACN_Stocktwits_sentiment_Jul_19_0702197af4.png" alt="ACN Stocktwits sentiment Jul 19.png" width="1318" height="318"><figcaption>ACN Stocktwits sentiment Jul 19</figcaption></figure>JPMorgan Upgrades AnaptysBio (ANAB) to Overweight:&nbsp;JPMorgan upgraded AnaptysBio Inc to Overweight, with a price target of $69, up from $29. This significant upgrade reflects the potential of the company's lead candidate, rosnilimab.&nbsp;Rosnilimab is designed to treat rheumatoid arthritis and ulcerative colitis, and it has shown promise in clinical trials, according to Investing.com. Analysts are also particularly excited about the upcoming Phase 2b results for rosnilimab in rheumatoid arthritis, which are expected by mid-2025.Retail investors on Stocktwits are also extremely bullish on ANAB (81/100), likely due to the recent upgrade and the potential for upside. Notably, JPMorgan's upgrade suggests a potential 103% upside from the current stock price.<figure class="image"><img style="aspect-ratio:1320/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANAB_Stocktwits_sentiment_Jul_19_ff3e590ce1.png" alt="ANAB Stocktwits sentiment Jul 19.png" width="1320" height="320"><figcaption>ANAB Stocktwits sentiment Jul 19</figcaption></figure>&nbsp;&nbsp;

Wall Street Bets Big On ARM, ACN, ANAB: Do Retail Investors Concur?

Analysts have issued upgrades for Arm (ARM), Accenture (ACN), and AnaptysBio (ANAB). Here’s how the Stocktwits community reacted.

Equity

The Analyst Landscape: 7 Takes On AnaptysBio

Latest Ratings for ANAB
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
 View More...

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings...

AnaptysBio (NASDAQ:ANAB) Given New $28.00 Price Target at JPMorgan Chase & Co.

AnaptysBio (NASDAQ:ANAB - Free Report) had its price target trimmed by JPMorgan Chase & Co. from $30.00 to $28.00 in a report issued on Monday, Benzinga reports. The firm currently has a neutral...

AnaptysBio price target lowered by $2 at JPMorgan, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $3,324,513.20 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB  Get Free Report) CEO Daniel Faga sold 145,940 shares of the businesss stock in a transaction dated Friday, March 22nd. The shares were sold at an average...

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $64,260.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB  Get Free Report) CEO Daniel Faga sold 3,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42...

AnaptysBio (ANAB, $21.67) price exceeded its 50-day Moving Average on March 22, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

AnaptysBio (ANAB, $21.67) price may climb as it broke lower Bollinger Band on Mar 22, 2024

This price move could be a signal that ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Volume	288,205.00
52-Wk High	$38.85
52-Wk Low	$13.36

ANAB AnaptysBio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals